Michael S. Wyzga
Known title: DirectorCIK: 0001201256
Michael S. Wyzga's purchase track record
Michael S. Wyzga has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/18/2023 | XFOR | $30K | -31.4% | -21.0% | +14.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| XFOR | ▲ Buy | Grant | 1,500 | $0 | 6/9/2025 | View on chart |
| MREO | ▲ Buy | Grant | 25,050 | $100K | 6/17/2024 | View on chart |
| XFOR | ▲ Buy | Grant | 45,000 | $0 | 6/10/2024 | View on chart |
| XFOR | ▲ Buy | Open Market | 25,000 | $30K | 8/18/2023 | View on chart |
| XFOR | ▲ Buy | Grant | 45,000 | $0 | 6/13/2023 | View on chart |
| XFOR | ▲ Buy | Grant | 6,667 | $0 | 6/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround
X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround. X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.